Skip to content
  • BiotechReality JobFinder
  • Market Analysis
  • Publish on BiotechReality
  • linkedin
  • facebook
  • instagram
  • twitter
BiotechReality
BiotechReality – Information Intelligence System for Biopharma
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
Popular
#FDA #Eli Lilly and Company #Johnson&Johnson #Clinical Data #Cancer #FDA Approval #Novo Nordisk #Hoffmann-La Roche

Category: Healthcare & Pharmaceuticals

Clinical Trials Healthcare & Pharmaceuticals News

Amgen Released Phase 3 MINT Trial Data Evaluating the Efficacy and Safety of UPLIZNA® (inebilizumab-cdon)

  • By Editor's Desk
  • 14 March 2025
amgen

The trial achieved its primary endpoint, as previously revealed at the 2024 American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting.

Tagged Amgen, inebilizumab, UPLIZNA®
Healthcare & Pharmaceuticals Clinical Trials News

Merck Announces Positive Results of Phase 3 Trials for Their HIV-1 Investigational Two-Drug Regimen Doravirine/Islatravir

  • By Editor's Desk
  • 13 March 2025
Merck MSD

Islatravir, Merck’s investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), inhibits HIV-1 replication through a variety of mechanisms

Tagged HIV, Investigational Drug, Merck & Co
Healthcare & Pharmaceuticals Research

Researchers Developed a More Affordable, Lower-risk Polio Vaccine

  • By Editor's Desk
  • 12 March 2025
vaccine vial image

The current inactivated polio vaccine (IPV), which uses a destroyed form of the poliovirus to trigger an immune system response

Tagged Polio, Polio Vaccine
Clinical Trials Cancer Healthcare & Pharmaceuticals News

Pfizer With Arvinas Announced Positive Results of Phase 3 VERITAC-2 Clinical Trial for Advanced or Metastatic Breast Cancer

  • By Editor's Desk
  • 11 March 2025
pfizer news

At the time of the analysis, less than 25% of the necessary number of events had taken place, indicating that overall survival was not mature.

Tagged Pfizer, VERITAC
Clinical Trials Healthcare & Pharmaceuticals News Weight-loss Drugs

Novo Nordisk’s CagriSema for Obesity and Type 2 Diabetes Shows Superior Results in REDEFINE 2 Trial

  • By Editor's Desk
  • 10 March 2025
novo nordisk

CagriSema showed a statistically significant and superior weight loss at week 68 compared to placebo, meeting the trial’s primary aim.

Tagged CagriSema, Novo Nordisk, REDEFINE
Healthcare & Pharmaceuticals Clinical Trials

Johnson & Johnson Discontinued VENTURA Drug Development Program

  • By Editor's Desk
  • 8 March 2025
JohnsonAndJohnson

The Phase 3 VENTURA research study, which was assessing aticaprant as an adjunctive treatment for major depressive disorder (aMDD), has been discontinued by Johnson & [Read More…]

Tagged Johnson&Johnson, VENTURA Drug Development
Healthcare & Pharmaceuticals Research

Over-the-counter Painkillers Were Associated With Better Concussion Recovery

  • By Editor's Desk
  • 7 March 2025
Over-the-counter Painkillers

The study merely demonstrates a connection rather than proving that painkillers enhance concussion recovery.

Tagged OTC, Painkillers
Regulatory Healthcare & Pharmaceuticals News

Roche’s Supplemental Biologics License Application of Gazyva/Gazyvaro (Obinutuzumab) for The Treatment of Lupus Nephritis Accepted by U.S. FDA

  • By Editor's Desk
  • 6 March 2025
Roche

In a randomized phase III study, Gazyva®/Gazyvaro® is the only anti-CD20 monoclonal antibody that shows a full renal response benefit.

Tagged BLA, FDA, Hoffmann-La Roche, Obinutuzumab
Anti-obesity Drugs Business News

AbbVie Enters Into the Obesity Drug Market With a License Agreement

  • By Editor's Desk
  • 5 March 2025
AbbVie

GUB014295 is a calcitonin and amylin receptor-specific agonist that may be a long-acting amylin analog.

Tagged AbbVie, Anti-obesity drugs, Obesity Drug Market
Healthcare & Pharmaceuticals News

“Healthy Skepticism” A New Ad Campaign from Lilly Against Compounded Drugs

  • By Editor's Desk
  • 2 March 2025
Eli Lilly and Company Ad campaign

Two blockbuster weight loss drugs including Lilly’s Zepbound were in U.S. FDA’s drugs shortage list.

Tagged Ad Campaign, Eli Lilly and Company, US FDA Shortage List

Posts navigation

← Older Posts
→ Newer Posts
Advertisement

Areas Covered

  • Anti-obesity Drugs
  • Artificial Intelligence
  • Astrobiology
  • Autoimmune Diseases
  • Biochemistry
  • Bioengineering
  • Bioinformatics
  • Biologics
  • Biosimilars
  • Biostatistics
  • Biotechnology
  • Blog
  • Business
  • Cancer
  • CDMO
  • Cell Biology
  • Clinical Data
  • Clinical Investigation
  • Clinical Trials
  • Collection
  • CRO
  • Deep Learning
  • Diabetes
  • Diagnostic Tests
  • Disease Biology
  • Diseases
  • Drug Discovery
  • Drugs
  • Engineering
  • Epidemiology
  • Gene Therapy
  • General Biology
  • Genetics
  • Genomics
  • Healthcare & Pharmaceuticals
  • Immunology
  • Immunotherapy
  • Instrumentation
  • Laboratory Info
  • Legal and Patent Affairs
  • Life Sciences
  • Machine Learning
  • Manufacturing
  • Medical Devices
  • Mental Health
  • Merger & Acquisitions
  • Microbiology
  • Microscopy
  • Molecular Biology
  • Nanotechnology
  • Neuroscience
  • News
  • Oncology
  • Pharmacology
  • Rare Diseases
  • Regenerative Medicine
  • Regulatory
  • Regulatory Approval
  • Research
  • Science
  • Science Communication
  • Supply Chain
  • Technology
  • Therapies
  • Toxicology
  • Vaccines
  • Virology
  • Weight-loss Drugs

Discover More

FDA Announces AstraZeneca Truqap Prostate Cancer Approval for PTEN-Deficient Patients
News Healthcare & Pharmaceuticals Oncology Regulatory Approval

FDA Announces AstraZeneca Truqap Prostate Cancer Approval for PTEN-Deficient Patients

13 June 202614 June 2026
Regulatory Intelligence Desk
Johnson & Johnson TALVEY Multiple Myeloma Treatment Shows Unprecedented Phase 3 MonumenTAL-3 Efficacy
Clinical Data Healthcare & Pharmaceuticals News Oncology

Johnson & Johnson TALVEY Multiple Myeloma Treatment Shows Unprecedented Phase 3 MonumenTAL-3 Efficacy

13 June 202613 June 2026
Clinical Trials & Data Desk
Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark
Business Technology

Novo Nordisk IT Security Incident: Unauthorized System Access Detected in Denmark

12 June 202612 June 2026
BiotechReality Business Intelligence Desk
Danaher Acquisition of Masimo Completed in $9.9B Diagnostics Mega-Deal
Merger & Acquisitions Business Healthcare & Pharmaceuticals News

Danaher Acquisition of Masimo Completed in $9.9B Diagnostics Mega-Deal

11 June 202611 June 2026
BiotechReality Business Intelligence Desk
AstraZeneca Advances Oral GLP-1 RA Elecoglipron Asset into Phase III Programme Following Robust Phase IIb Results
Anti-obesity Drugs Clinical Data Clinical Trials News

AstraZeneca Advances Oral GLP-1 RA Elecoglipron Asset into Phase III Programme Following Robust Phase IIb Results

9 June 20269 June 2026
Clinical Trials & Data Desk
Johnson & Johnson Firefly Bio Acquisition: JNJ Acquires Firelink DAC Platform for $1 Billion
Business Healthcare & Pharmaceuticals Merger & Acquisitions News

Johnson & Johnson Firefly Bio Acquisition: JNJ Acquires Firelink DAC Platform for $1 Billion

8 June 20269 June 2026
BiotechReality Business Intelligence Desk
Advertisement
BiotechReality JobFinder

  • Clinical Research Associate – AstraZeneca
    13 June 2026
  • Regulatory Affairs Manager – Sanofi
    12 June 2026
  • Validation Services Project Manager – Sartorius
    10 June 2026
  • Scientific Writer – Toxicology | Eli Lilly and Company
    8 June 2026
  • Senior Scientist – Novartis
    6 June 2026

BiotechReality Shots Weekly Newsletter

Processing…
Success! You're on the list.
Whoops! There was an error and we couldn't process your subscription. Please reload the page and try again.
SciRealityPress BiotechReality

A SciRealityPress Associate

Contents in the website is licensed under CC BY-NC 4.0

Disclaimer: The content on this website is not meant to provide medical or any other professional advice. Understand and use the information, double check if necessary. All trademarked names mentioned in the contents belongs to their respective owners. Stock exchange data providing by Stockdio

SciRealityPress © 2026
  • About
  • Contact
  • Privacy Policy
  • Terms & Conditions
  • Disclaimer
  • Platform Status
  • Market Analysis
  • Healthcare & Pharmaceuticals
    • Business
    • Pharmacology
  • Clinical Trials
    • Regulatory Approval
  • Biotechnology
    • Molecular Biology
    • Genomics
    • Immunology
    • Microbiology
      • Virology
    • Diagnostic Tests
  • Science
    • Microbiology
    • Research
    • General Biology
  • Technology
    • Artificial Intelligence
  • News
    • Research
  • Newsletters
  • linkedin
  • facebook
  • instagram
  • twitter